Venture Kick
Venture Kick is a private philanthropic initiative based in Zurich, Switzerland, founded in 2007 to support Swiss startups at the pre-seed stage. It provides up to 150,000 Swiss francs in funding and offers structured entrepreneurial training aimed at developing sustainable businesses. Entrepreneurs participate in a competitive process, pitching their ideas up to three times for increasing funding amounts, while receiving valuable feedback from expert juries. To date, Venture Kick has supported 600 startup projects with a total of 24.9 million francs, leading to the incorporation of 454 active companies that have created over 6,000 jobs and attracted approximately 2.49 billion francs in subsequent investments. Companies founded by Venture Kick alumni have notably achieved significant recognition, with 55 percent of the TOP 100 Swiss Startup Award in 2018 represented by these ventures. In 2019, the initiative aimed to allocate 4.35 million francs to support idea-stage projects, facilitating the transition of Swiss scientific innovations to global markets.
Top Stages
Past deals in Healthcare
Clee Medical
Grant in 2025
Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.
Carewell
Grant in 2025
Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
Scanvio
Grant in 2025
Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.
Azure Cell Therapies
Grant in 2024
Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases
BLEEDnFIRE Therapeutics
Grant in 2024
BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments
Translation-X
Pre Seed Round in 2024
Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.
ValTech Lifesciences
Grant in 2024
ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.
Deegtal
Grant in 2024
dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone.
Regenosca
Pre Seed Round in 2024
Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.
TrueYouOmics
Convertible Note in 2024
TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.
Pace Locator
Grant in 2024
Pace Locator is a medical technology company that specializes in developing advanced imaging software. Its flagship product, also named Pace Locator, uses electrocardiogram (ECG) and echocardiogram (ECHO) data to generate 3D maps of the heart. This innovative tool helps healthcare professionals localize the source of cardiac arrhythmias and visualize the location of cardiac implantable electronic device (CIED) leads, enabling faster and more accurate diagnoses.
HeroSupport
Grant in 2023
HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.
AlpineWell
Grant in 2023
AlpineWell developing novel solutions to hunger and swallowing difficulties, AlpineWell produces patient-centric food for special medicinal purposes (FSMP) and also provides automatic nutrition tracking to detect malnutrition early on.
Transpire Bio
Grant in 2023
Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving healthcare outcomes globally. The company specializes in the commercialization of lower-cost generic alternatives for injectable drugs, utilizing innovative delivery methods to enhance patient experience by providing painless administration. Transpire Bio's product portfolio includes medicines and inhalation therapies targeting both lung diseases and systemic conditions, reflecting its commitment to addressing a wide range of health challenges through advanced biopharmaceutical solutions.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Ocumeda
Grant in 2022
Ocumeda is a telemedical network specializing in ophthalmology, providing accessible eye screening services through collaborations with opticians, retirement homes, and companies. The company employs board-certified ophthalmologists who conduct medical assessments remotely, utilizing a secure cloud platform. Additionally, Ocumeda integrates medical artificial intelligence products to enhance the screening process, enabling opticians and pharmacies to detect conditions that may lead to blindness and vision loss. By lowering barriers to eye examinations, Ocumeda aims to improve overall eye health and accessibility to care.
Sensawear
Grant in 2022
Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.
SightIn Health
Grant in 2022
SightIn Health is a company that specializes in the development of artificial intelligence-powered software designed for portable ultrasound applications. Founded in 2021 and based in Geneva, Switzerland, the company focuses on enhancing the capabilities of ultrasound machines by providing advanced image analytics, usage guidance, and interpretation of patient diagnostics. Its platform automates quality assessment and ultrasound probe guidance, effectively lowering the skill barrier required for healthcare professionals to operate ultrasound equipment. By streamlining the process of capturing and interpreting medical imaging, SightIn Health aims to improve the accuracy of medical diagnostics and prognostics in healthcare settings.
Maven Health
Non Equity Assistance in 2022
Maven Health is a health technology company that provides an innovative metabolic health solution aimed at healthcare providers. The company employs saliva as the bio-fluid for analyzing metabolites through advanced Nuclear Magnetic Resonance (NMR) spectrometry, utilizing proprietary analytical methods. This approach allows for a comprehensive assessment of individuals' metabolic health with minimal invasiveness and at a competitive cost. By delivering results via an intuitive data platform, Maven Health enables healthcare professionals to effectively identify individuals at risk for metabolic disorders who may not be detected through conventional healthcare practices.
FimmCyte
Grant in 2022
FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on Endometriosis. The company aims to accelerate the path toward a cure for endometriosis by addressing significant healthcare requirements and advancing novel ideas in women's health. FimmCyte's mission is to empower women to take control of their health and meet their unmet medical needs through cutting-edge treatments.
SURI BioTech
Grant in 2022
SURI BioTech is a biotechnology company focused on the development of health-promoting bacterial strains designed to alleviate bloating and intestinal discomfort. The company's proprietary strains work by reducing the production of hydrogen gas by intestinal microorganisms, providing potential therapeutic benefits for various functional gastrointestinal disorders, including infant colic and lactose intolerance. SURI BioTech employs a scientific approach to create probiotics that specifically target gastrointestinal health, thereby offering solutions for individuals suffering from digestive issues. Their innovative platform contributes to ongoing advancements in the treatment of gastrointestinal illnesses.
OptimaRatio
Grant in 2022
OptimaRatio liberates chronic and rare disease patients from managing their complex health data.
NextImmune
Grant in 2022
NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.
Avelo
Grant in 2022
Avelo is a manufacturer of breath aerosol diagnostic equipment focused on providing rapid testing solutions for infectious diseases. The company has developed a non-invasive sample-to-answer breath test that reliably detects multiple lower respiratory tract infections within minutes. This process involves three simple steps, allowing healthcare providers to make timely and informed decisions regarding antibiotic or antiviral treatments. Avelo's innovative approach aims to enhance the speed and accuracy of diagnoses in primary care settings, ultimately contributing to improved patient outcomes and the potential to save lives through early intervention.
YLAH
Grant in 2022
YLAH is a technology company specializing in the development of web and mobile solutions for psychotherapists and their patients. Its core offerings include individualized therapy tools, clinical assessment platforms, and health monitoring systems, empowering therapists to efficiently scale their services using digital means.
NexMR
Grant in 2022
NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
NexMR
Grant in 2022
NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.
Adaptyv Bio
Pre Seed Round in 2022
Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.
Galventa
Convertible Note in 2022
Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.
Sensemodi
Grant in 2022
Sensemodi is a developer of an AI-powered smart wearable device that specializes in assessing joint health, particularly focusing on the knee and other joints. The device utilizes a combination of thermal, acoustic, and kinematic data through multiple sensor modalities to provide a quick and comprehensive evaluation of joint conditions. By facilitating easy monitoring and assessment of joint health, Sensemodi aims to prevent disability and alleviate the socioeconomic burden associated with musculoskeletal disorders. This technology empowers patients to track their joint health conveniently, ultimately leading to improved healthcare outcomes.
Adiposs
Seed Round in 2021
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
Bottneuro
Grant in 2021
Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.
ArcoScreen
Grant in 2021
ArcoScreen is a Swiss medtech company focused on advancing drug discovery through its innovative microfluidic platform. This platform specializes in drug screening that targets cell membrane receptors, offering a faster and more efficient method for conducting chip-based GPCR assays. By enabling the identification of a drug's mode of action directly on patient cells, ArcoScreen's technology allows for the simultaneous testing of proteins that make up the drugs, assessing their efficacy in a single test. This approach aims to facilitate the treatment of complex diseases such as cancer, Alzheimer's, and diabetes, ultimately enhancing the drug development process for researchers.
Galventa
Convertible Note in 2021
Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.
Resmonics
Grant in 2021
Resmonics is a technology company established in October 2020 as a spin-off from ETH Zürich and the University of St. Gallen. The company specializes in developing a privacy-friendly acoustic artificial intelligence system that analyzes soundscapes to detect symptoms of infectious lung diseases. Its flagship product line, Quorum, integrates this AI technology with air quality sensors and noise analytics, aiming to foster healthy and productive environments. Resmonics' technology is particularly focused on chronic disease management, offering solutions for triage and monitoring of nocturnal respiratory symptoms. By providing clinically validated insights and early warnings for respiratory crises through a mobile application, Resmonics enhances patient safety and health management.
CustomSurg
Grant in 2021
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Neurosoft Bioelectronics
Seed Round in 2021
Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.
Rea Diagnostics
Pre Seed Round in 2020
Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.
Regenosca
Pre Seed Round in 2020
Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.
CustomSurg
Convertible Note in 2020
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Aseptuva
Grant in 2020
Aseptuva is an early-stage MedTech startup located in Technopark Winterthur, focused on combating Healthcare-Associated Infections (HAI). The company addresses the critical issue of catheter-related infections that can lead to severe complications, including pneumonia and bloodstream infections, which claim thousands of lives annually and incur significant healthcare costs. Aseptuva is developing a range of medical devices designed for in-situ disinfection of various catheters, effectively preventing the onset of infections in healthcare settings. By providing an automated system for disinfection, Aseptuva aims to support medical staff in reducing the risk of hospital-acquired infections, thereby improving patient outcomes and potentially saving thousands of lives each year. Through its innovative technology, the company aspires to establish a new standard in critical care and make a meaningful impact on global health.
Axentless
Grant in 2020
Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.
CustomSurg
Grant in 2020
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Helvitek Labs
Grant in 2020
Helvitek Labs is a Lausanne-based start-up founded in 2019 by Théo-Tim Denisart and Roberto Costa. The company specializes in the development of a new generation of urban anti-pollution masks designed to address the health challenges posed by fine particle pollution. Inspired by the severe air quality issues encountered during trips to China, the founders aimed to create masks that not only protect users from pollutants but also enhance comfort for health professionals who wear respirators for extended periods. Helvitek Labs incorporates artificial intelligence to improve the seal between the mask and the user's face, along with advanced filtering and sealing technologies. This innovative approach is designed to alleviate the psychological pressure and physical strain typically associated with traditional masks. The company has garnered support through various grants and awards, allowing it to establish its operations in the EPFL Innovation Park and assemble a dedicated team. Helvitek Labs was officially incorporated as a Société Anonyme in March 2020.
LifeMatrix
Grant in 2020
LifeMatrix is a biotechnology company focused on the development of biomimetic implants and bio-engineering technologies aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company specializes in human cell-derived, off-the-shelf tissue-engineered implants that integrate with the patient's body post-implantation, allowing them to grow and regenerate. This innovative approach addresses the limitations of traditional implants, promoting faster recovery and improved outcomes for patients. LifeMatrix's technology is supported by over 20 years of research, resulting in more than 100 peer-reviewed publications and extensive preclinical studies demonstrating safety and efficacy, paving the way for clinical applications. The company's advancements are bolstered by various national and international research grants, reflecting its commitment to transforming the field of regenerative medicine.
Emovo
Pre Seed Round in 2020
Emovo Care SA is a medical device company based in Lausanne, Switzerland, founded in 2020. It specializes in developing accessible robotic devices aimed at assisting individuals with hand motor impairments, particularly those recovering from stroke. The company's flagship product is an active orthosis designed for hemiparetic stroke patients, allowing them to practice hand movements in the comfort of their homes. Emovo's orthosis utilizes innovative technology initially developed during doctoral research at EPFL, which garnered significant attention for its advancements in brain-computer interfaces. The device is complemented by a mobile application that tracks usage and motivates patients, enhancing engagement for individuals, clinicians, and health insurance providers alike, thereby aiming to improve overall care outcomes. Emovo Care SA holds ISO 13485 certification, underscoring its commitment to quality in the medical device sector.
Adiposs
Pre Seed Round in 2020
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
Nutrix
Grant in 2020
Nutrix is a Swiss health-tech company based in Basel, founded in 2019, that specializes in developing innovative healthcare solutions. The company's flagship product is a nanosensor that is placed on the tooth to measure glucose levels in saliva, which communicates data to an external application. This technology not only tracks food intake but also offers dietary recommendations to help prevent diabetes. Nutrix aims to enhance health monitoring through precision medicine by combining advanced AI with wearables and digital coaching. In 2025, the company plans to launch CortiSense, a non-invasive cortisol monitoring sensor, further expanding its range of health monitoring solutions. By providing cost-effective and user-friendly tools, Nutrix seeks to empower individuals to manage their health proactively, reducing the need for frequent medical consultations.
Flowbone
Grant in 2020
Flowbone is a Swiss company based in Lausanne that specializes in the development and promotion of injectable biomaterials aimed at preventing fractures in fragile bones. Its innovative technology focuses on minimal-invasive augmentation, allowing weak bones to strengthen themselves without disrupting natural bone mechanics or blood flow. The company's biomaterials are designed to stimulate the body's self-healing capabilities, addressing the needs of patients with chronic insufficiency fractures and optimizing bone health, particularly in spine surgery. Flowbone's mission is to enhance the quality of life and independence for the elderly, helping them avoid the severe consequences associated with fragility fractures.
Regenosca
Grant in 2020
Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.
MimiX Biotherapeutics
Grant in 2020
MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.
STIMIT
Pre Seed Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.
Genknowme
Pre Seed Round in 2020
Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.
SurgeonsLab
Grant in 2020
SurgeonsLab is a Swiss company founded in 2020, based in Bern, that specializes in developing and producing patient-specific training models for surgical procedures and validating new medical devices. The company focuses on microsurgery and micro-interventions, offering solutions for treatment planning and strategy. SurgeonsLab's innovative devices are designed to enhance precision in surgeries and clinical interventions, enabling medical trainees to improve their skills through high-end technology that serves as an alternative to traditional human and animal models. By facilitating testing and planning for surgical interventions, SurgeonsLab aims to ultimately enhance patient safety and outcomes in the medical field.
EarlySight
Grant in 2020
EarlySight SA is a Swiss medical device company established in 2016 and headquartered in Lausanne. It specializes in developing advanced imaging technology to aid in the early detection and treatment of eye diseases. The company's innovative eye fundus camera utilizes cellular-level imaging and transscleral illumination to provide detailed images of the retina, allowing for the detection of minor structural changes. This technology enables eye specialists to monitor treatment effects rapidly and non-invasively, enhancing their ability to visualize the morphology of retinal cells. EarlySight aims to bring its cutting-edge solutions to clinics, thereby improving patient outcomes in ophthalmology.
Inanna Fertility
Grant in 2020
Inanna Fertility develops a clinical decision support platform designed to enhance the outcomes of in-vitro fertilization treatments. The company's innovative platform utilizes machine learning algorithms and a comprehensive global patient database to deliver data-driven insights that facilitate personalized treatment recommendations. These recommendations are dynamically adjusted according to each patient's unique medical history and response to treatment. By providing this tailored support, Inanna aims to alleviate the physical, emotional, and financial burdens faced by couples undergoing fertility treatments, positioning itself as a leader in the realm of fertility clinic solutions.
Terapet
Grant in 2020
Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.
Neurosoft Bioelectronics
Grant in 2020
Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.
Testmate Health
Grant in 2020
Testmate Health is a medtech startup and an award-winning spin-off from the University of Geneva, Switzerland. The company has developed a smartphone-compatible platform that offers a test kit capable of diagnosing diseases with identifiable DNA or RNA sequences without laboratory involvement, providing rapid results at home in minutes. Their initial product is a user-friendly, all-in-one kit that serves as the first rapid urine self-test for the four most common sexually transmitted diseases (STDs). Given that one million new STDs are diagnosed daily, Testmate Health addresses a critical gap in the market, as traditional testing often requires lab processing and can take up to a week for results. The kit not only delivers immediate results but also allows users to scan their results with a smartphone, facilitating quick access to treatment if necessary. Additionally, Testmate Health has plans to expand its offerings with test kits for other diseases, empowering individuals to manage their health conveniently from home.
deepCDR Biologics
Pre Seed Round in 2020
deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.
Swiss Medical Union
Grant in 2020
Swiss Medical Union SA is a healthcare technology company based in Yverdon-les-Bains, Switzerland, founded in 2019. The company specializes in the manufacture of Micro-Bioreactors, which are used to test the interaction, efficiency, and safety of new medical products using models of human organs and tissues. This innovative equipment enables the selection of appropriate therapies ex vivo tailored to individual patient needs. In addition to its bioreactor technology, Swiss Medical Union develops software that simulates the activity of multiple organs, facilitating real-time analysis of interactions between active products and specific human organs. This technology allows monitoring of the effects of injected products within the circulatory system. The company also offers clinical testing services to hospitals, healthcare institutions, government clients, and international clinical facilities, supporting medical professionals in making informed decisions, particularly in cancer treatment.
deepCDR Biologics
Grant in 2020
deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.
autonomyo
Grant in 2020
Autonomyo is a Swiss company founded in 2014, based in Lausanne, that specializes in developing robotic rehabilitation solutions for individuals with neurological gait disorders. The company focuses on manufacturing a lightweight exoskeleton designed to facilitate robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. Autonomyo's team, comprised of engineers, developers, and healthcare professionals, is dedicated to enhancing accessibility and training intensity for people with neuromuscular and motor disorders, ultimately aiming to improve their mobility and restore their freedom of movement.
C-MedTec
Grant in 2020
C-MedTec is a company focused on enhancing the detection and monitoring of brain concussions through innovative technology. It has developed a specialized helmet that serves as a medical imaging modality capable of measuring brain metabolism and identifying abnormal neurological behavior following a traumatic impact. This advancement addresses the significant gap in concussion diagnosis, which traditionally relies on subjective assessments by trained professionals. By providing early detection and diagnosis, C-MedTec aims to promote safer sports practices and mitigate the risk of long-term effects and chronic conditions such as Alzheimer's disease and chronic traumatic encephalopathy (CTE). Through its cutting-edge approach, the company seeks to improve health outcomes for athletes and individuals at risk of brain trauma.
Galventa
Grant in 2020
Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.
KOVE medical
Grant in 2019
KOVE Medical is a MedTech company focused on advancing fetal treatment. It specializes in developing an implantable medical device designed to close and secure the hole created in the fetal membrane during fetoscopic procedures. This innovation aims to prevent membrane rupture, thereby reducing the risk of premature delivery associated with such treatments. By enabling safer and more effective fetal interventions, KOVE Medical seeks to enhance the outcomes for unborn children undergoing critical care.
Pregnolia
Grant in 2019
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.
Adiposs
Pre Seed Round in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
anavo medical
Grant in 2019
Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.
Synendos Therapeutics
Pre Seed Round in 2019
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.
Artiria Medical
Seed Round in 2019
Artiria Medical SA, established in 2019 and headquartered in Lausanne, Switzerland, specializes in developing innovative medical devices for treating vascular diseases. Its flagship product is a micro-actuated device designed to navigate deep into brain arteries, facilitating precise navigation and stroke treatment. This technology empowers catheters and guidewires, enabling surgeons to perform complex procedures with enhanced control and precision, ultimately saving lives.
frater.swiss
Seed Round in 2019
Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.
KaleiBox
Grant in 2019
KaleiBox is a company based in Zurich, Switzerland, specializing in the development of three-dimensional optical imaging devices specifically designed for small-animal imaging. It offers two main products: the standalone-mode KaleiBox and a hybrid-mode KaleiBox, both of which facilitate fluorescence tomography with an emphasis on compact hardware design and advanced software. The company's devices serve various applications, including research laboratories, biotechnological industries, agricultural diagnostics, and image-guided surgical procedures. Drawing inspiration from the kaleidoscope, KaleiBox focuses on versatility and portability, aiming to enhance the current workflow in 3D fluorescence imaging, particularly for preclinical studies.
Auxivo
Seed Round in 2019
Auxivo AG is a Swiss company based in Zürich that specializes in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing the physical strain and fatigue associated with such work, Auxivo's products aim to enhance worker safety and well-being, ultimately minimizing the risk of injuries. The company's focus on creating accessible exoskeletons underscores its commitment to improving workplace conditions and ensuring the long-term health of its users.
OxyPrem
Pre Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.
OxyPrem
Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.
Alibion
Grant in 2019
Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.
Adiposs
Grant in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
anavo medical
Grant in 2019
Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.
Araris Biotech
Pre Seed Round in 2019
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.
Invasight
Seed Round in 2019
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
STIMIT
Grant in 2019
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.
Araris Biotech
Grant in 2019
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.
KOVE medical
Seed Round in 2019
KOVE Medical is a MedTech company focused on advancing fetal treatment. It specializes in developing an implantable medical device designed to close and secure the hole created in the fetal membrane during fetoscopic procedures. This innovation aims to prevent membrane rupture, thereby reducing the risk of premature delivery associated with such treatments. By enabling safer and more effective fetal interventions, KOVE Medical seeks to enhance the outcomes for unborn children undergoing critical care.
frater.swiss
Seed Round in 2019
Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.
Synendos Therapeutics
Pre Seed Round in 2019
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.
Artiria Medical
Seed Round in 2019
Artiria Medical SA, established in 2019 and headquartered in Lausanne, Switzerland, specializes in developing innovative medical devices for treating vascular diseases. Its flagship product is a micro-actuated device designed to navigate deep into brain arteries, facilitating precise navigation and stroke treatment. This technology empowers catheters and guidewires, enabling surgeons to perform complex procedures with enhanced control and precision, ultimately saving lives.
Genknowme
Grant in 2019
Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.
ALAnostics
Pre Seed Round in 2019
ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.
Hi-D Imaging
Grant in 2019
Hi-D Imaging AG is a Swiss company established in 2019, specializing in advanced imaging technologies for cardiovascular disease, particularly focusing on heart valve replacement. The company offers a SaaS-based pre-operational planning platform that assesses the hemodynamics of patient-specific anatomies. This platform enables physicians to analyze blood flow patterns and select the optimal size and shape of heart valves prior to trans-catheter aortic valve implantation. By providing detailed imaging and in-vitro fluid dynamic analysis, Hi-D Imaging empowers medical professionals to make data-driven decisions tailored to individual patient needs, thereby improving surgical outcomes and reducing the necessity for additional medical imaging. The company is headquartered in Winterthur, Switzerland.
Invasight
Grant in 2019
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
Auxivo
Pre Seed Round in 2019
Auxivo AG is a Swiss company based in Zürich that specializes in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing the physical strain and fatigue associated with such work, Auxivo's products aim to enhance worker safety and well-being, ultimately minimizing the risk of injuries. The company's focus on creating accessible exoskeletons underscores its commitment to improving workplace conditions and ensuring the long-term health of its users.
B-rayZ
Grant in 2019
B-rayZ is a company that originated as a spin-off from the University Hospital Zurich, focusing on the intersection of artificial intelligence and medical imaging. Comprising a team of professional radiologists, data scientists, and physicians with extensive experience in radiology, B-rayZ specializes in developing predictive deep learning analytical tools and algorithms. Their software is designed to assist radiologists specifically in the area of mammography, providing real-time assessments of image quality and breast density. This technology facilitates accurate and standardized evaluations of medical imaging data, ultimately enhancing breast cancer detectability. By equipping specialists with intelligent tools, B-rayZ aims to improve the detection of breast cancer while also contributing to the reduction of healthcare costs.
EraCal
Seed Round in 2019
EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.
Artiria Medical
Grant in 2019
Artiria Medical SA, established in 2019 and headquartered in Lausanne, Switzerland, specializes in developing innovative medical devices for treating vascular diseases. Its flagship product is a micro-actuated device designed to navigate deep into brain arteries, facilitating precise navigation and stroke treatment. This technology empowers catheters and guidewires, enabling surgeons to perform complex procedures with enhanced control and precision, ultimately saving lives.
frater.swiss
Grant in 2019
Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.
KOVE medical
Grant in 2019
KOVE Medical is a MedTech company focused on advancing fetal treatment. It specializes in developing an implantable medical device designed to close and secure the hole created in the fetal membrane during fetoscopic procedures. This innovation aims to prevent membrane rupture, thereby reducing the risk of premature delivery associated with such treatments. By enabling safer and more effective fetal interventions, KOVE Medical seeks to enhance the outcomes for unborn children undergoing critical care.
Synendos Therapeutics
Grant in 2018
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.